Severe generalised haemorrhage associated with plasma proteolytic activity after thoracic surgery, operations for hyperplasia or carcinoma of the prostate, gastrointestinal or pancreatic resection, and other operations was reported in the early 1950s.1-3 Such plasma proteolytic activity is usually part of a disseminated intravascular coagulation syndrome. Sometimes, however, the local fibrinolytic activity in the area of the operation or trauma disturbs haemostasis and wound healing. This activity is not usually pathological but is a physiological one in different tissues and body fluids. 
Antifibrinolytic drugs
When antifibrinolytic drugs became clinically available about 20 years ago interest focused on their possible effect on urinary tract haemorrhage. It was independently reported that treatment with epsilon-aminocaproic acid (EACA) reduced bleeding after prostatectomy.12-'4 Andersson15 investigated the blood loss during the first three 24-hour periods after transvesical prostatectomy in three groups each of 25 patients. In one group EACA was given in a total dose of 14 g over three days, in another the patients received the drug in a varying but larger dose (on average 51 g over three days), and in the third no antifibrinolytic drug was given. In the control group the postoperative blood loss averaged 494 ml, in the smaller-dose group it averaged 182 ml (370% of the controls), and in the larger-dose group it averaged 91 ml (180% of the controls). The operative blood loss was not influenced by the medication.
McNicol et al. 13 reported that EACA given in a total dose of 8 g in the first 12 postoperative hours reduced postoperative blood loss by 500% after suprapubic prostatectomy and by 75 % after transurethral resection. Vinnicombe and Shuttleworth16 found that postoperative haemorrhage in a randomised series of patients subjected to retropubic prostatectomy was reduced to approximately onethird in patients given EACA 6 g in 12 hours compared with that in untreated controls.
Tranexamic acid (aminomethyl cyclohexane carboxylic acid (AMCA)) is a stronger inhibitor of plasminogen activation than EACA. In a randomised double-blind trial Hedlund17 studied the postoperative blood loss after transvesical prostatectomy in patients given AMCA in a total dose of either 6 g or 12 g or a placebo at the start of the operation and continuing for the first four postoperative days. The average postoperative blood loss in the patients given 12 g AMCA was 480%
(p< 0-01) and in those given 6 g 53 % (p< 0-02) of the blood loss in the placebo patients.
It has been debated whether antifibrinolytic therapy increases the risk of postoperative thromboembolism. Hedlund,18 using the 1251-fibrinogen uptake test, found no significant difference in the incidence of thrombosis between the patients on AMCA and those on placebo. This corresponds with the findings of Vinnicombe and Shuttleworth19 and Becker and Borgstrdm,20 who used other diagnostic methods. Nevertheless, thromboembolism in patients on antifibrinolytic drugs has been described, as with all kind of prostatic surgery. In manifest phlebothrombosis antifibrinolytic treatment retards lysis of the thrombus and thus aggravates the condition. It should therefore be discontinued in patients with evidence of thromboembolism.
Aiming to reduce the fibrinolytic activity in the prostatic cavity and obviate the risk of thrombosis with systemic antifibrinolytic therapy, Vecsey, Bankuti, and Czuczor2l and Vecsey, Bankuti, and Palfy22 gave AMCA intravenously during the operation and as a continuous bladder irrigation postoperatively. When a 1 % solution of AMCA was used for the irrigation the 24-hour blood loss after transvesical prostatectomy was reduced from an average of 376 ml in an untreated control group to an average of 47-4 ml (13 %). For prophylaxis the patients were given 500 ml Rheomacrodex during the operation and on postoperative days 1, 2, and 3. No cases of thromboembolism occurred.
Bleeding is a threat in prostatic surgery in patients with coagulation defects or dysfibrinogenaemia. The risk may be countered in part by antifibrinolytic therapy.23 Renal bleeding is sustained and prolonged by the fibrinolytic activity of urine. Antifibrinolytic drugs, however, should be given with the utmost caution in bleeding from the upper urinary tract because of the risk of clot retention in the kidney. 24 In cases of so-called essential haematuria or haemorrhage after kidney trauma, when the bleeding is slight but protracted, antifibrinolytic treatment can be given with relative safety and often successfully. 25 There is evidence that antifibrinolytic treatment reduces blood loss after dental extractions in patients with coagulation defects,26 after tonsillectomy,27 28 
